Toxicities Associated with Sacituzumab Govitecan

Data from multiple sources provide insights into the safety profile of #Sacituzumab #Govitecan (SG), identifying common hematologic toxicities and unexpected #AdverseEffects, underscoring the need for critical clinical monitoring & management.

Read: doi.org/10.1007/s115...

Novel TROP2 ADC Sacituzumab Tirumotecan Shows Promising Results in Urothelial Carcinoma A recent Phase II study published in the Annals of Oncology highlights the efficacy of sacituzumab tirumotecan, offering new hope for patients with advanced urothelial carcinoma.

Novel TROP2 ADC Sacituzumab Tirumotecan Shows Promising Results in Urothelial Carcinoma #China #Chengdu #Kelun-Biotech #Sacituzumab #Urothelial_Carcinoma

Kelun-Biotech Showcases Promising Clinical Findings for TROP2 ADC in Cancer Treatment at CCHIO 2025 At the 2025 CCHIO Congress, Kelun-Biotech revealed compelling outcomes from various clinical trials on its TROP2 ADC, sacituzumab tirumotecan.

Kelun-Biotech Showcases Promising Clinical Findings for TROP2 ADC in Cancer Treatment at CCHIO 2025 #China #ADC #Kelun-Biotech #Sacituzumab #Kunming

#PinkOctober - #ASCENT-05: Phase III study investigates whether #Sacituzumab #Govitecan in combination with #Pembrolizumab can further improve outcomes compared to physician’s choice of standard therapy in pts with early TNBC who still have residual invasive disease after NACT and surgery

Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan Published in NEJM The New England Journal of Medicine reveals significant findings from the Phase III OptiTROP-Lung04 study on sacituzumab tirumotecan for NSCLC, highlighting its efficacy.

Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan Published in NEJM #China #Chengdu #Sacituzumab #NSCLC #EGFR-TKI

Clinical Breakthrough: Phase II Study on Novel NSCLC Therapy Published in Nature Medicine Recent findings from a Phase II study reveal promising results for a novel treatment regime for advanced non-small cell lung cancer (NSCLC), combining sacituzumab tirumotecan and tagitanlimab.

Clinical Breakthrough: Phase II Study on Novel NSCLC Therapy Published in Nature Medicine #China #Chengdu #Sacituzumab #NSCLC #Tagitanlimab

Kelun-Biotech Reports Strong Financial Performance and Pipeline Advances for 2025 Kelun-Biotech has announced impressive interim results for 2025, showing significant revenue growth and advancements in oncology and non-oncology pipeline projects amidst a shifting biopharmaceutical landscape.

Kelun-Biotech Reports Strong Financial Performance and Pipeline Advances for 2025 #China #Chengdu #oncology #Kelun-Biotech #Sacituzumab

Breakthrough Results for Kelun-Biotech's Sacituzumab Tirumotecan in Top Medical Journal Sichuan Kelun-Biotech announces significant findings on sacituzumab tirumotecan (sac-TMT), published in Nature Medicine, marking a major advancement for cancer treatment.

Breakthrough Results for Kelun-Biotech's Sacituzumab Tirumotecan in Top Medical Journal #China #Chengdu #Kelun-Biotech #Sacituzumab #TROP2_ADC

Kelun-Biotech's Sacituzumab Tirumotecan Gains Approval for Second Lung Cancer Indication Sichuan Kelun-Biotech has received marketing approval for Sacituzumab Tirumotecan, increasing treatment options for patients with EGFR-positive NSCLC.

Kelun-Biotech's Sacituzumab Tirumotecan Gains Approval for Second Lung Cancer Indication #China #Chengdu #Kelun-Biotech #Sacituzumab #Lung_Cancer

Kelun-Biotech's Sacituzumab Tirumotecan Gains Chinese Approval for Advanced TNBC Treatment Kelun-Biotech announces its innovative drug, Sacituzumab Tirumotecan, receives marketing approval for advanced TNBC in China, marking a significant milestone.

Kelun-Biotech's Sacituzumab Tirumotecan Gains Chinese Approval for Advanced TNBC Treatment #China #Chengdu #Kelun-Biotech #Sacituzumab #TNBC